

Special Issue

Emerging Biomarkers and Molecular Characterization of Renal Cancers

Message from the Guest Editors

Molecular characterizations and immunohistochemistry of renal tumors have evolved significantly within the last decade. Advances in this field continue to allow us to classify previously unclassified renal tumors and improve several previous classifications. While tumor morphology remains the main driver of treatment, clinical trials are increasingly taking molecular signature into account. Data from these trials allow for further clinicopathological correlation, highlighting groups of patients who may benefit from personalized therapy. This Special Issue will bring together studies on biomarkers, molecular findings, and related diagnostic approaches of renal tumors. In addition, we welcome studies with future perspective approaches involving novel technology, such as artificial intelligence and machine learning.

Guest Editors

Dr. Eric A. Singer

Division of Urologic Oncology, Urologic Oncology Fellowship Program,
The Ohio State University Comprehensive Cancer Center, 915
Olentangy River Road, Suite 3100, Columbus, OH 43212, USA

Dr. Evita Sadimin

Department of Pathology, City of Hope National Medical Center, Duarte,
CA, USA

Deadline for manuscript submissions

closed (31 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/145507

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)